Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 6/20 | 0.43 |
| ▸ | FGFR4 | P22455 | 6/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | FDPS | P14324 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 3/20 | 0.40 |
| ▸ | PPARA | Q07869 | 2/20 | 0.40 |
| ▸ | DAPK1 | P53355 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGAV | P06756 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6016455 | 1.00 | HDAC6 (0.43) | HDAC6FGFR1FGFR4SYKFDPS | |
| SCHEMBL5840142 | 0.89 | HDAC6 (0.47) | HDAC6FGFR1FGFR4FDPSPPARA | |
| SCHEMBL6807059 | 0.84 | TDP1 (0.45) | SYKITGB3ITGAV | |
| SCHEMBL4640030 | 0.84 | TDP1 (0.45) | SYKITGB3ITGAV | |
| SCHEMBL4640164 | 0.83 | ITGB3 (0.46) | ITGB3ITGAV | |
| SCHEMBL27524220 | 0.83 | ITGB3 (0.46) | ITGB3ITGAV | |
| SCHEMBL4640844 | 0.82 | ITGB3 (0.48) | ITGB3ITGAV | |
| SCHEMBL4644200 | 0.82 | BTK (0.42) | SYKITGB3ITGAVMAPT | |
| SCHEMBL6805719 | 0.82 | BTK (0.42) | SYKITGB3ITGAVMAPT | |
| SCHEMBL4640795 | 0.81 | SLC29A1 (0.38) | SYKCTSKCTSLCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1210348-B9 | NAPHTHYRIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | AVENTIS PHARMA GMBH (DE) | 2006-04-26 | — | — | EP | disclosed |
| EP-1210348-B1 | NAPHTHYRIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | AVENTIS PHARMA GMBH (DE) | 2005-09-28 | — | — | EP | disclosed |
| US-20040198718-A1 | Naphthyridine derivatives, processes for their preparation, their use and pharmaceutical compositions comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH | 2004-10-07 | — | — | US | disclosed |
| US-6743800-B1 | VITRONECTIN RECEPTOR ANTAGONISTS AND INHIBITORS OF CELL ADHESION; OSTEOPOROSIS, ANGIOGENESIS INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-06-01 | — | — | US | disclosed |
| EP-1210348-A1 | NAPHTHYRIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | Aventis Pharma Deutschland GmbH (DE) | 2002-06-05 | — | — | EP | disclosed |
| WO-2001002398-A1 | NAPHTHYRIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-01-11 | — | — | WO | disclosed |
| EP-1065207-A1 | Naphthyridine derivatives, processes for their preparation, their use, and pharmaceutical compositions comprising them | Aventis Pharma Deutschland GmbH (DE) | 2001-01-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198718-A1 | Naphthyridine derivatives, processes for their preparation, their use and pharmaceutical compositions comprising them | VCAM1, ADGRF1, ADGRE5 | HDAC6 3040/4885FGFR1 675/4885FGFR4 1068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.